



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Board has been ordered and called for **Wednesday, August 20, 2025, at 9:00 a.m.** at the Board office, for the purpose to wit:

A G E N D A

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 08-14-2025 (Rev2)

1. Call to Order
2. Invocation & Pledge of Allegiance
3. Quorum Call
4. Call for Additional Agenda Items & Adoption of Agenda
5. Consideration of Draft Minutes from Previous Meeting: May 7, 2025
6. Report on Action Items
7. Confirmation of Acts
8. Opportunity for Public Comment
9. Special Orders of the Day
 - A. Presentation of Gold Certificates
 - (1) Peggy D. King - PST.010648
 - (2) Lawrence D. LeDuff – PST.010650
 - (3) Richard J. Oubre – PST.010657
 - (4) Gerald P. Pannell – PST.010658
 - (5) Gerard M. Johnson – PST.010709
 - (6) Richard A. Soileau – PST.010719
10. Committee Reports
 - A. Finance – Mr. Soileau ([Committee Agenda](#))
 - (1) Presentation – Russ Champagne, CPA & Penny Scruggins, CPA with Champagne and Co., LLC
 - (2) Consideration of Unaudited *Compiled Financial Statements for Fiscal Year 2024-2025*
 - B. Application Review – Ms. Melancon
 - C. Reciprocity – Mr. Mannino
 - (1) [List](#) of Pharmacists Licensed by Reciprocity
 - D. Violations – Mr. Indovina
 - (1) Consideration of Proposed Voluntary Consent Agreements
 - a. Case No. 25-0074 – PHY.008230 – Daniel Pharmacy, LLC d/b/a Daniel Pharmacy +
 - b. Case No. 25-0076 – PST.024203 – Patrick Joseph LaBorde
 - c. Case No. 25-0070 – PST.022121 – Dwayne Emile Hammer, Jr.
 - d. Case No. 24-0341 – PHY.006047 – Bocage Pharmacy Centre, Inc. – dba Bocage Pharmacy

NOTE: Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a person, (2) strategy sessions or negotiations with respect to litigation, (3) discussions regarding the report, development, or course of action regarding security personnel, plans, or devices, including discussions concerning cybersecurity plans, financial security procedures, and assessment and implementation of any such plans or procedures, (4) investigative proceedings regarding allegations of misconduct, or other purposes itemized at La. R.S. 42:17.

NOTE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

NOTE: To request a disability accommodation, please contact Joe Fontenot, Executive Director, at 225.925.6496 or email at jfontenot@pharmacy.la.gov.

D. Violations (**Continued**)

(1) Consideration of Proposed Voluntary Consent Agreements (**Continued**)

- e. Case No. 24-0342 – PST.014051 – Marc Devereaux Gibbens
- f. Case No. 24-0302 – PBM.000053 – True Rx Management Services, Inc.
- g. Case No. 25-0043 – PBM.000045 – WellDyneRx, LLC
- h. Case No. 24-0219 – PBM.000032 – Script Care Ltd

E. Impairment – Ms. Hall ([Committee Agenda](#))

- (1) Consideration of Committee Recommendations re Applications
- (2) Consideration of Committee Recommendations re Addictionists

F. Reinstatement – Dr. Strong ([Committee Agenda](#))

- (1) Consideration of Committee Recommendations re Applications
- (2) Reinstatements by Board Policy Since Last Meeting

G. Tripartite – Mr. Resweber

H. Regulation Revision – Dr. Cloud

- (1) Consideration of Regulatory Proposal 2025-A: Prescription Drug Delivery – [Draft #3](#)
- (2) Consideration of Regulatory Proposal 2024-K: Centralized Prescription Dispensing – [Draft #4](#)
- (3) Consideration of Regulatory Proposal 2025-D: Prescription Monitoring Program (PMP) Record Retention – [Draft #1](#)
- (4) Consideration of Regulatory Proposal 2025-F: Controlled Dangerous Substances – [Draft #2](#)

I. Executive Committee – Mr. McKay ([Committee Agenda](#))

- (1) Review & Consideration of *Compliance Questionnaire* for Annual Legislative Audit
- (2) Review & Consideration of *Annual Report*
- (3) Review of Comments from the Public Hearing held on June 26, 2025 (LA R.S. 49:964(B))
- (4) Consideration of Committee Recommendations re Policy & Procedure Manual
 - a. Proposed Repeal *PPM.I.B.3.b – Open Meetings by Electronic Means – PBM Monitoring Advisory Council*
 - b. Proposed Revision *PPM.I.B.6 – Board Liaisons to Other Entities – Draft #1*
 - c. Proposed Revision *PPM.I.C.1 – Executive Committee – Expense Report Guidelines – Travel Budget – Draft #1*
 - d. Proposed Revision *PPM.II.D.2.a – Record Retention Schedule, Item No. 308 – Criminal History Information – Draft #1*
- (5) Request for Rescission and Expungement of Board Action
- (6) Consideration of Office of Public Health Pharmacy Procedures – R.S. 37:933
- (7) Notice of *Exceptions Report*
- (8) Consideration of Committee Recommendations – See [Committee Agenda](#) for Items

NOTE: Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a person, (2) strategy sessions or negotiations with respect to litigation, (3) discussions regarding the report, development, or course of action regarding security personnel, plans, or devices, including discussions concerning cybersecurity plans, financial security procedures, and assessment and implementation of any such plans or procedures, (4) investigative proceedings regarding allegations of misconduct, or other purposes itemized at La. R.S. 42:17.

NOTE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

NOTE: To request a disability accommodation, please contact Joe Fontenot, Executive Director, at 225.925.6496 or email at jfontenot@pharmacy.la.gov.

11. Staff Reports

A. General Counsel – Mr. Finalet

(1) Consideration of Proposed Voluntary Consent Agreements & Surrenders

- a. Case No. 25-0140 – CPT.016454 – Amy Marisha Comeaux
- b. Case No. 25-0143 – CPT.013346 – Kayla Renee Champagne
- c. Case No. 25-0133 – CPT.014333 – D'Tonya Dalinda Spottsville
- d. Case No. 25-0141 – CPT.016887 – Madison Clair Cormier
- e. Case No. 25-0131 – PST.023319 – Tramaine Preston Smith
- f. Case No. 25-0148 – CPT.015364 – Tiara Von'Kitra Pembroke
- g. Case No. 25-0153 – CPT.017709 – Destiny Shianne Snyder
- h. Case No. 25-0151 – CPT.016386 – Shea Lynn Williams
- i. Case No. 25-0146 – CPT.010046 – Anastaisia Yvette Jordan
- j. Case No. 25-0139 – CPT.017634 – Joshe' Shade' Brown
- k. Case No. 25-0147 – CPT.017242 – Stephenique Moenicia Moore
- l. Case No. 25-0149 – CPT.011190 – Chelsea Ann Robertson
- m. Case No. 25-0145 – CPT.014980 – Princess Louella Hughes
- n. Case No. 25-0144 – CPT.007195 – Meredith Kelly Fleck

B. Executive Director – Mr. Fontenot

- (1) Prescription Monitoring Program (PMP) – [Quarterly Report](#)
- (2) Consideration of *Requests for Exemptions* from PMP Reporting
- (3) Credentials – [Census Report](#), [New Credentials Issued](#)
- (4) Compliance Division – [Complaint Investigation Monitor](#)
- (5) [Bulletin No. 25-01](#): Act 657 (2024 Regular Session) – Emergency Medications
- (6) [Bulletin No. 25-02](#): Legislative Update – 2025 Regular Session

12. New Agenda Items Added During Meeting

13. Announcements

14. Adjourn

NOTE: Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a person, (2) strategy sessions or negotiations with respect to litigation, (3) discussions regarding the report, development, or course of action regarding security personnel, plans, or devices, including discussions concerning cybersecurity plans, financial security procedures, and assessment and implementation of any such plans or procedures, (4) investigative proceedings regarding allegations of misconduct, or other purposes itemized at La. R.S. 42:17.

NOTE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

NOTE: To request a disability accommodation, please contact Joe Fontenot, Executive Director, at 225.925.6496 or email at jfontenot@pharmacy.la.gov.